Disease · MONDO_0024327

chronic renal failure syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic renal failure syndrome. Diseases, record MONDO_0024327. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024327

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic renal failure syndrome; Open Targets
Open Targets ID: MONDO_0024327; Open Targets
Other names: CRF - chronic renal failure, chronic kidney failure, chronic renal failure, chronic renal failure disease, kidney failure, chronic; Open Targets
MeSH: D051436; MeSH
NCI Thesaurus: C9438; NCI Thesaurus
Highest stage of its drugs: Approval, for 11 of its 34 drugs, from EMA Human Drugs and PMDA; Open Targets

Drugs34

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EPOETIN ALFA	CHEMBL1201565	Protein	Approval	EMA Human Drugs	7	4	3	Drugs and targets
DARBEPOETIN ALFA	CHEMBL1201566	Protein	Approval	EMA Human Drugs	4	2	1	Drugs and targets
EPOETIN BETA	CHEMBL2109092	Protein	Approval	EMA Human Drugs	3	2	0	Drugs and targets
EPOETIN THETA	CHEMBL2108290	Protein	Approval	EMA Human Drugs	2	0	0	Drugs and targets
EPOETIN ZETA	CHEMBL2108593	Protein	Approval	EMA Human Drugs	2	0	0	Drugs and targets
BIXALOMER	CHEMBL4297202	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
EPOETIN DELTA	CHEMBL2109093	Protein	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
FERUMOXYTOL	CHEMBL1201867		Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
LANTHANUM CARBONATE	CHEMBL2096647	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	CHEMBL3707314	Protein	Approval	EMA Human Drugs	1	0	0	Drugs and targets

1 to 10 of 34

See all 34 drugs

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EPOR	Erythropoietin receptor	8	Erythropoietin receptor agonist	Approval	https://conductscience.org/library/genes/2057	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Unknown	https://conductscience.org/library/genes/2280	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2	HMG-CoA reductase inhibitor	Phase 2	https://conductscience.org/library/genes/3156	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
SERPINC1	Antithrombin-III	2	Antithrombin-III activator	Phase 2/3	https://conductscience.org/library/genes/462	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
AVPR2	Vasopressin V2 receptor	1	Vasopressin V2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/554	Drugs and targets
EGLN1	Hypoxia-inducible factor prolyl hydroxylase	1	Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/54583	Drugs and targets
EGLN2	Hypoxia-inducible factor prolyl hydroxylase	1	Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/112398	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials26

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00598442	Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis	Phase 3	493	2012-07-30	Chronic Renal Failure, Chronic Kidney Disease, Anemia	PEGINESATIDE	Its record names the disease	ClinicalTrials.gov
NCT02331680	A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration	Phase 2	124	2019-10-22	Chronic Renal Failure	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT00680043	Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA	Phase 2	114	2012-05-30	Anemia, Chronic Renal Failure, Chronic Kidney Disease	EPOETIN ALFA, PEGINESATIDE	Its record names the disease	ClinicalTrials.gov
NCT01876381	A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration	Phase 2	26	2018-08-24	Chronic Renal Failure	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT01936519	Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.	Not applicable	24	2021-01-12	Immunosuppression, Renal Failure	EVEROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01895322	Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis	Phase 2	20	2016-01-01	Chronic Renal Failure	TOLVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT01090037	TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)	Phase 2/3	892		Chronic Renal Failure, Glomerular Disease, Nephrosclerosis	BERAPROST SODIUM	Its record names the disease	ClinicalTrials.gov
NCT06492031	Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients		439		Chronic Renal Failure	DEXTROSE, ICODEXTRIN	Its record names the disease	ClinicalTrials.gov
NCT00221845	Effect of Strict Blood Pressure Control and ACE-Inhibition on Progression of Chronic Renal Failure in Pediatric Patients	Phase 3	400		Children, Chronic Renal Failure, Hypertension, Acquired Kidney Disease, Congenital Kidney Disease	RAMIPRIL	Its record names the disease	ClinicalTrials.gov
NCT04075916	A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients	Phase 2	201		End Stage Renal Disease	SOFOSBUVIR, VELPATASVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 26

See all 26 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Calcineurin Inhibitor and Mycophenolic Acid vs Everolimus and Mycophenolic Acid: deaths from any cause	0 of 12	0 of 12	24	NCT01936519	Trial comparisons
Calcineurin Inhibitor and Mycophenolic Acid vs Everolimus and Mycophenolic Acid: serious adverse events	0 of 12	1 of 12	24	NCT01936519	Trial comparisons

Papers from its trials22

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23343062	RESULT	1	PubMed
16093916	RESULT	1	PubMed
15772249	RESULT	1	PubMed
15647341	RESULT	1	PubMed
15253732	RESULT	1	PubMed
14744931	RESULT	1	PubMed
14630977	RESULT	1	PubMed
39790231	DERIVED	1	PubMed
37846607	DERIVED	1	PubMed
37119829	DERIVED	1	PubMed

1 to 10 of 22

See all 22 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0024327

GET https://conductscience.org/api/diseases/v1/MONDO_0024327/drugs?page=2

API reference For AI assistants